Cabozantinib not checked

Exelixis · XL184 · XL-184

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
26 active
37 in total · 31 in the EU
Targets
—
None known yet

What this is

How it works
Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
How it’s given
“Tablets containing 60-mg or 20-mg cabozantinib once daily orally.”In the company’s words, NCT03690388 on ClinicalTrials.gov
Tested for
Differentiated Thyroid Cancer (2 trials), Hepatocellular Carcinoma (2 trials), Renal Cell Carcinoma (2 trials), Colorectal Cancer (2 trials), Medullary Thyroid Cancer, Metastatic Prostate Cancer, Prostate Adenocarcinoma, Cancer and 17 more
Main trialPhase 4
“The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a 60 mg dose compared with a 140 mg dose in subjects with progressive, metastatic MTC. It will test if the lower dose results in similar progression free survival (PFS) and overall response rate (ORR) with fewer adverse events compared to the PFS, ORR and adverse events found in previous clinical trials of 140 mg.”In the company’s words, NCT01896479 on ClinicalTrials.gov
Other names
XL184 · Cabometyx · XL-184

Other drugs for Differentiated Thyroid Cancer

All 3 drugs for Differentiated Thyroid Cancer

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials37

TrialPhaseCompletesWhat it tests
Phase 4Active, not recruiting 15 Jul 2020 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
Phase 3Active, not recruiting 19 Aug 2020 A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Phase 3Active, not recruiting 30 Nov 2021 Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
Phase 3Active, not recruiting 31 Jan 2022 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Phase 3Active, not recruiting 19 Apr 2024 Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
Phase 3Enrolling by invitation 31 May 2030 Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Phase 1Active, not recruiting 21 Feb 2023 Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 3Completed 22 May 2015 A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
Phase 3Completed 16 Oct 2017 Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Phase 2Terminated May 2011 Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Phase 2Completed May 2013 Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Phase 2Terminated Nov 2014 Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
Phase 3Authorised not given CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Phase 2Authorised not given Immunological variables associated to ICI toxicity in cancer patients
Phase 3Authorised not given Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)
Phase 2Authorised not given A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)
Phase 2Authorised not given PEMBROCABOSARC : COMBINATION OF PEMBROLIZUMAB AND CABOZANTINIB IN PATIENTS WITH ADVANCED SARCOMAS
Phase 2Authorised not given Cabozantinib plus Durvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2, single-arm proof-of-concept trial: ARCADIA study
Phase 2Authorised not given MegaMOST - A multicenter, open-label, biology driven, Phase II study evaluating the activity of anti-cancer treatments targeting tumor molecular alterations/characteristics in advanced / metastatic tumors
Phase 2Ended not given CABONEN – a phase II trial of Cabozantinib in patients with advanced, low proliferative NEN G3
Phase 2Ended not given Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.
Phase 2Ended not given A phase II, open-label, multicenter trial to investigate the clinical activity and safety of Cabozantinib in combination with avelumab in patients refractory to standard chemotherapy with advanced neuroendocrine neoplasias G3 (NEN G3)
Phase 2Authorised not given A phase 2 open label study of caBozantinib in patients with advanced or unresectable Renal cEll cArcinoma pretreated with one immunochecKPOint INhibiTor (anti PD1/PDL1).
Phase 3Authorised not given Strategic treatment Pause of first-line Immune Check point inhibitor + Inhibitor in good or only one adverse prognostic factor in intermediate risk metastatic renal cell carcinoma (mRCC) with an objective response: a randomized, non-inferiority phase III study - SPICI
Phase 2Authorised not given A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET): The LOLA trial
Phase 4Authorised not given Cabozantinib and Nivolumab among older patients with renal-cell carcinoma, a prospective cohort with geriatric, pharmacologic and patient-reported-outcome evaluation (CABOLD)
Phase 2Ended not given Efficacy and safety of Cabozantinib in patients with hepatocellular carcinoma progressing on or intolerant to prior treatment with immune checkpoint inhibitors: A phase II study (Immunocabo)
Phase 4Authorised not given CLINICAL AND HUMORAL IMPACT OF PRIMARY TUMOR ABLATION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH IMMUNOTHERAPY.THE ITALIC-RCC RANDOMIZED STUDY
Phase 2Authorised not given Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation
Phase 4Authorised not given Digital monitoring of self-reported symptoms by patients treated with Cabozantinib plus Nivolumab for advanced clear-cell renal carcinoma: The CANIQOL multicentre study
Phase 2Ended not given A phase II trial of an individualized treatment strategy for patients with metastatic non-clear cell renal carcinoma
Phase 2Authorised not given SKIPP2: Cabozantinib Dose Skipping as an Alternative to Dose Reductions
Phase 4Authorised not given Randomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy _ POG
Phase 3Authorised not given Sequence Strategy of Immuneoncology (IO-IO) vs IO-tyrosine kinase inhibitors (TKI) followed by TKI in metastatic renal cell carcinoma (mRCC): A randomized phase 3 study Meet uro and FICOG trial. COMBO-Seq trial.
Phase 4Authorised not given Intensified Monitoring of PhArmacology of Cabozantinib as a tool for Toxicity management in patients with renal cell carcinoma
Phase 2Not authorised not given The role of serum KIM-1 and MAdCAM-1 dynamics in early prediction of the efficacy of de-escalated systemic treatment in advanced renal cell carcinoma (STELA study).
Phase 2/3Authorised not given The HCC patient-journey study: a prospective, adaptive, master protocol, to assess the value of the available sequences of treatment for patients with advanced hepatocellular carcinoma. The Journey of liver cancer patient - J-LI
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Cabozantinib

Following is part of Solo: you see every change to Cabozantinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in